◀ Back to EPHB2
EPHB2 — RPS6KB1
Text-mined interactions from Literome
Balasubramanian et al., J Biol Chem 2003
(Cardiomegaly) :
Studies using specific inhibitors and dominant negative c-Raf expression in cardiomyocytes indicate that the
S6K1 activation
involves mTOR,
MEK/ERK , and phosphatidylinositol 3-kinase pathways and is independent of protein kinase C and c-Raf
Altamirano et al., J Endocrinol 2009
(Calcium Signaling...) :
ERK1/2 inhibitor PD98059
blocked the testosterone induced
S6K1 phosphorylation, whereas Akt inhibition ( Akt-inhibitor-X ) had no effect
Arellano-Plancarte et al., Biochem Pharmacol 2010
(Insulin Resistance) :
Studies using the specific MEK inhibitor, PD98059, revealed that
ERK1/2 activation also
mediates Ang II-induced
S6K-1 and IRS-1 phosphorylation, and the impairment of Akt Thr ( 308 ) and GSK-3alpha/beta phosphorylation
Palaniappan et al., Mol Cell Endocrinol 2013
:
Inhibition of
ERK1/2 signaling
caused partial reduction of insulin induced phosphorylation of
RPS6KB1 and RPS6 whereas inhibition of PI3-kinase signaling completely blocked the insulin response